Form 4: Twist Bioscience Exec Sells Shares for Tax Obligations

Twist Bioscience's Chief Legal Officer, Dennis Cho, sold 6,515 shares of common stock to cover tax withholding obligations related to vested performance stock units.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp (TWST), reported a transaction involving company common stock.
• On October 30, 2025, Cho sold 6,515 shares of TWST common stock at a price of $31.4443 per share.
• This sale was a non-discretionary 'sell to cover' transaction, mandated by the company's equity incentive plans to satisfy tax withholding obligations upon the vesting of Performance Stock Units (PSUs).
• Following this transaction, Cho beneficially owns 121,713 shares of Twist Bioscience common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax obligations related to executive compensation, not indicative of a change in sentiment towards the company or its future prospects.

Positives

• The transaction was a non-discretionary 'sell to cover' for tax withholding, not a voluntary sale by the executive, indicating no change in investment sentiment.
• The executive continues to hold a significant number of shares (121,713) after the transaction, maintaining alignment with shareholder interests.

Negatives

• The executive's direct beneficial ownership of common stock decreased by 6,515 shares.

Future Outlook

NA

Industry Context

This transaction is a routine insider filing related to executive compensation, common across various industries for employees receiving equity awards. It does not provide specific insights into broader industry trends or competitive positioning.

Key Dates

Recommendation

The reported transaction is a routine 'sell to cover' for tax withholding purposes related to vested performance stock units, which is a common practice for executive equity compensation. It does not reflect a discretionary sale by the executive or provide new information that would alter the fundamental investment thesis for Twist Bioscience Corp. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for a change in stock valuation.

Keywords

Twist Bioscience, TWST, Form 4, insider transaction, stock sale, executive compensation, performance stock units, tax withholding